Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
FDF
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
Annual Reports
NA
1. Batmen
2. Dermatop
3. Hoe 777
4. Hoe-777
5. Peitel
6. Prednisolone-17-ethylcarbonate-21-propionate
1. Dermatop
2. 73771-04-7
3. Hoe 777
4. Hoe-777
5. Dermatop E Emollient
6. S-770777
7. Mls002154121
8. V901lv1k7d
9. Las189961
10. S 77 0777
11. S-77 0777
12. Las-189961
13. Nsc-760042
14. Peitel
15. Las-41003 Component Prednicarbate
16. Unii-v901lv1k7d
17. S-77-0777
18. Prednicarbato
19. Prednicarbatum
20. [2-[(8s,9s,10r,11s,13s,14s,17r)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Propanoate
21. Dermatop (tn)
22. Prednicarbate (usp/inn)
23. Prednicarbatum [inn-latin]
24. Prednicarbat
25. Prednicarbato [inn-spanish]
26. Ncgc00016926-01
27. Einecs 277-590-3
28. Prednicarbate [usan:usp:inn:ban]
29. Cas-73771-04-7
30. Prestwick0_001044
31. Prestwick1_001044
32. Prestwick2_001044
33. Prestwick3_001044
34. Prednicarbate [mi]
35. Prednicarbate [inn]
36. Schembl3941
37. Dsstox_cid_25502
38. Dsstox_rid_80919
39. Prednicarbate [usan]
40. Dsstox_gsid_45502
41. Bspbio_000968
42. Prednicarbate [vandf]
43. Prednicarbate [mart.]
44. S 770777
45. Spbio_002904
46. Prednicarbate [usp-rs]
47. Prednicarbate [who-dd]
48. Bpbio1_001066
49. Gtpl7605
50. Chembl1200386
51. Dtxsid9045502
52. Chebi:135791
53. Hms1571a10
54. Hms2098a10
55. Hms2230o11
56. Hms3715a10
57. Prednicarbate [orange Book]
58. Hy-b1365
59. Zinc3938652
60. Prednicarbate [ep Monograph]
61. Tox21_110687
62. Prednicarbate [usp Monograph]
63. Akos025402043
64. Prednicarbate For System Suitability A
65. Ac-3521
66. Ccg-221044
67. Db01130
68. Nsc 760042
69. 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 17-(ethyl Carbonate) 21-propionate
70. Ncgc00179357-01
71. Ncgc00179357-05
72. Pregna-1,4-diene-3,20-dione, 17-((ethoxycarbonyl)oxy)-11-hydroxy-21-(1-oxopropoxy)-, (11beta)-
73. Smr001233428
74. Ab00514017
75. Cs-0013106
76. D05601
77. 771p047
78. Sr-01000841201
79. Q-101379
80. Q4376623
81. Sr-01000841201-2
82. Brd-k46137903-001-03-3
83. 11.beta.,17,21-trihydroxypregna-1,4-diene-3,20-dione 17-(ethyl Carbonate) 21-propionate
84. Pregna-1,4-diene-3,20-dione, 17-((ethoxycarbonyl)oxy)-11-hydroxy-21-(1-oxopropoxy)-, (11.beta.)-
Molecular Weight | 488.6 g/mol |
---|---|
Molecular Formula | C27H36O8 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 9 |
Exact Mass | 488.24101810 g/mol |
Monoisotopic Mass | 488.24101810 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 982 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Dermatop |
PubMed Health | Prednicarbate (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Intermediate |
Drug Label | DERMATOP Ointment (prednicarbate ointment) 0.1% contains the non-halogenated prednisolone derivative prednicarbate. The topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic... |
Active Ingredient | Prednicarbate |
Dosage Form | Ointment |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Valeant Bermuda |
2 of 6 | |
---|---|
Drug Name | Dermatop e emollient |
PubMed Health | Prednicarbate (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Intermediate |
Drug Label | DERMATOP Ointment (prednicarbate ointment) 0.1% contains the non-halogenated prednisolone derivative prednicarbate. The topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic... |
Active Ingredient | Prednicarbate |
Dosage Form | Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Valeant Bermuda |
3 of 6 | |
---|---|
Drug Name | Prednicarbate |
Active Ingredient | Prednicarbate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Fougera Pharms |
4 of 6 | |
---|---|
Drug Name | Dermatop |
PubMed Health | Prednicarbate (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Intermediate |
Drug Label | DERMATOP Ointment (prednicarbate ointment) 0.1% contains the non-halogenated prednisolone derivative prednicarbate. The topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic... |
Active Ingredient | Prednicarbate |
Dosage Form | Ointment |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Valeant Bermuda |
5 of 6 | |
---|---|
Drug Name | Dermatop e emollient |
PubMed Health | Prednicarbate (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Intermediate |
Drug Label | DERMATOP Ointment (prednicarbate ointment) 0.1% contains the non-halogenated prednisolone derivative prednicarbate. The topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic... |
Active Ingredient | Prednicarbate |
Dosage Form | Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Valeant Bermuda |
6 of 6 | |
---|---|
Drug Name | Prednicarbate |
Active Ingredient | Prednicarbate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Fougera Pharms |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA Label
Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocytes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation also are inhibited by corticosteroids.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC18 - Prednicarbate
Absorption
Absorbed systemically across the stratum corneum.
Primarily in skin
In common with other topical corticosteroids, prednicarbate has anti-inflammatory, antipruritic, and vasoconstrictive properties. In general, the mechanism of the anti-inflammatory activity of topical steroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?